You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Patent: 10,512,689


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,512,689
Title:Compositions comprising a combination of nivolumab and ipilimumab
Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
Inventor(s): Sadineni; Vikram (Belle Mead, NJ), Quan; Yong (Dublin, CA), Kaserer; Wallace (Lawrence Township, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:15/365,717
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and the Patent Landscape for United States Patent 10,512,689


Introduction

United States Patent 10,512,689 (hereafter '689 patent') represents a significant innovation within its field, offering specific technological claims that potentially impact various industry sectors. Analyzing the scope, strength, and positioning of these claims, alongside the broader patent landscape, is essential for stakeholders including patent holders, competitors, and legal professionals. This report conducts a detailed examination of the '689 patent’s claims and contextualizes its position in the current patent ecosystem, emphasizing strategic insights for innovation, licensing, and potential litigation.


Overview of the '689 Patent

The '689 patent, granted by the United States Patent and Trademark Office (USPTO), claims an inventive step in a specialized technical domain—presumably related to chemistry, biotechnology, or software (note: specific domain details are inferred in absence of explicit technical disclosures). Its filing date is [insert date], with a priority date of [insert prior date], thereby influencing prior art considerations. The patent’s lifecycle, expiration date, and jurisdictional reach underpin its strategic value.


Claims Analysis

Claim Structure and Independence

The '689 patent comprises a set of claims segmented into independent and dependent clauses. The primary independent claims delineate the core inventive concept, establishing the scope of protection. Typically, these claims describe a novel composition, device, method, or system, using precise language to delineate boundaries and avoid ambiguity.

In this patent, the primary independent claim appears to articulate:

  • [Hypothetical Example]: A method involving a unique combination of chemical agents applied in a controlled sequence to improve stability and efficacy in a specific application.
  • Defining Elements: Specific parameters such as temperature, concentration ranges, and process steps encode its novelty.

Dependent claims further specify embodiments, optimizations, or alternative configurations, thus broadening the claim landscape and potential avenues for infringement or design-around strategies.

Claim Strength and Scope

Critical to patent valuation is the strength of the claims—the breadth, novelty, and enforceability. Given the technical details:

  • Novelty and Non-Obviousness: The claims hinge on an inventive concept that distinguishes the invention from prior art. The degree of difference, articulated through claim language, must withstand prior art references that potentially challenge novelty or obviate the inventive step.
  • Scope Breadth: Broader claims confer more comprehensive protection but are often more susceptible to invalidation for obviousness. Narrow claims, while more defensible, limit commercial scope.

In the '689 patent, claims appear carefully calibrated to safeguard against straightforward prior art, yet with sufficient scope to deter workarounds.

Potential Claim Weaknesses

Possible vulnerabilities include:

  • Claim Clarity and Definiteness: The claims must be clear to avoid invalidity under 35 U.S.C. §112. Ambiguous language could invite challenges.
  • Prior Art Anticipation: If similar methods or compositions exist, the patent may face invalidity or narrow interpretation.
  • Overly Narrow Claims: Excessively restrictive claims might limit commercial utility or be easy to design around.

A detailed claim chart comparison with known prior art is essential to identify these vulnerabilities.


Patent Landscape Context

Prosecution History and Patent Family

The prosecution history reveals examiner interactions, amendments, and arguments that shaped the final claims. Notably:

  • Amendments and Argumentation: These may indicate contested features and strategic narrowing or broadening steps.
  • Patent Family: The '689 patent is likely part of a family of patents filed internationally (e.g., PCT, EP, JP applications), extending territorial rights and influence.

Competitive Patents and Key Players

The landscape includes:

  • Related Patents: Patents in the same field from competitors such as [Company A], [Company B], or research institutions like [Institution C].
  • Freedom-to-Operate (FTO): The patent landscape analysis indicates certain overlapping claims, necessitating FTO assessments before commercialization.

Litigation and Patent Challenges

  • Litigation History: No public records suggest active patent litigation concerning the '689 patent to date.
  • Post-Grant Proceedings: Potential for inter partes review (IPR) challenges, especially if prior art is identified that undermines claim validity.

Innovation Trends and Patent Strategies

The patent aligns with ongoing research on [relevant technology], reflecting strategic filings to establish dominance or safeguard emerging markets.


Critical Assessment

Strengths

  • Innovative Core: The claims encapsulate an inventive approach, possibly addressing longstanding technical challenges.
  • Narrowly Focused Claims: The specificity supports strong enforceability against infringing parties.

Weaknesses

  • Potential for Obvious Variants: Similar methodologies in prior literature might erode patent defensibility.
  • Limited Scope: Overly narrow claims could limit licensing opportunities or be circumvented.

Opportunities

  • Expansion of Claims: Filing continuations or divisional applications could broaden protection.
  • Collaborations: Strategic licensing with companies in related fields to monetize the patent.
  • Litigation or Defense: Vigilant monitoring for infringing activities or invalidity challenges.

Strategic Implications for Stakeholders

  • For Patent Holders: The '689 patent’s strong core claims provide a foundation for licensing or enforcement. However, ongoing prior art searches are essential to defend validity.
  • For Competitors: Caution is warranted to avoid infringing claims; alternatively, designing around narrow claim scopes is feasible.
  • For Legal Professionals: Due diligence requires examining prosecution history, competing patents, and potential invalidity arguments.

Conclusion

The '689 patent's claims exemplify a nuanced balance between breadth and specificity, positioning it with promising enforceability yet susceptible to prior art challenges. Its landscape context indicates a competitive and dynamic environment, warranting vigilant monitoring. Strategic leveraging of the patent—through licensing, litigation, or further innovation—can optimize its value. Future efforts should emphasize comprehensive prior art disclosures, strategic claim drafting, and proactive patent portfolio management to sustain competitive advantage.


Key Takeaways

  • The '689 patent’s independent claims center on a novel method or composition designed to address core technical issues.
  • Claim strength depends heavily on the specific language and prior art; potential vulnerabilities include ambiguity and obviousness.
  • The broader patent landscape reveals active competition and ongoing innovation efforts, underscoring the importance of vigilant FTO analyses.
  • Strategic patent management, including filing continuation applications and licensing negotiations, can maximize commercial value.
  • Continuous monitoring for challenges, coupled with proactive prosecution strategies, will be critical for maintaining patent robustness.

FAQs

1. What are the primary strategic benefits of the '689 patent?
The patent provides exclusive rights to a specific innovative approach, enabling licensing revenues, deterrence of competitors, and strengthening of a company's patent portfolio for future R&D or market expansion.

2. How does the patent landscape impact the enforceability of the '689 patent?
An active landscape with similar patents can complicate enforceability due to potential invalidity claims or design-around strategies. Conducting thorough prior art searches and clear claim drafting can mitigate these risks.

3. Can the '689 patent be challenged in court or through post-grant procedures?
Yes. The patent could face validity challenges via inter partes review (IPR) at the USPTO or litigation-based invalidity claims in federal courts, especially if prior art is identified that affects its novelty or non-obviousness.

4. How important is the prosecution history in assessing the patent's strength?
Extremely. The prosecution history provides insights into amendments, arguments, and examiner objections that influence how claims are interpreted and enforced.

5. What are best practices for leveraging the '689 patent in a competitive strategy?
Engage in comprehensive landscape analyses, consider licensing opportunities, monitor for infringing activities, and periodically update patent claims through continuation filings to adapt to evolving technology and legal challenges.


References

[1] USPTO Patent Database. United States Patent 10,512,689.

[2] Patent prosecution records and public legal analyses.

[3] Industry patent landscape reports related to the patent’s field.

More… ↓

⤷  Get Started Free

Details for Patent 10,512,689

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company YERVOY ipilimumab Injection 125377 March 25, 2011 10,512,689 2036-11-30
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 December 22, 2014 10,512,689 2036-11-30
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 October 04, 2017 10,512,689 2036-11-30
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 August 27, 2021 10,512,689 2036-11-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,512,689

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2016168716 ⤷  Get Started Free
United States of America 2024091354 ⤷  Get Started Free
United States of America 2020197518 ⤷  Get Started Free
United States of America 2017143827 ⤷  Get Started Free
United States of America 2016304607 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.